Sandra Milligan
Independent DirectorDr. Sandra Milligan, M.D. J.D., also Known as Sandy, serves as Senior Vice President, Global Regulatory Affairs at Daiichi Sankyo, Inc. since February 2025. She was the Interim CEO of Aspira Women's Health Inc. since December 16, 2024 and served as its President since April 01, 2024 until February 21, 2025. She serves as an Independent Director at Gossamer Bio, Inc. since June 2021. She serves as an Independent Director at Spyre Therapeutics, Inc. since May 2024. She had been Head of Research & Development at Organon & Co. since June 2, 2021, until December 1, 2023 and was its Executive Vice President until December 1, 2023 & served as it's Senior Advisor since December 1, 2023, until January 5, 2024. Dr. Milligan joins Aspira from her role as Executive Vice President, Research and Development at Organon where she founded the R&D organization and advanced near-and long-term strategies for pipeline growth and value creation. Prior to Organon, she served as Senior Vice President, Global Regulatory Affairs and Clinical Safety at Merck where she developed and implemented proactive, worldwide strategies across a broad spectrum of therapeutics to enable rapid registration and robust life-cycle enhancement. Prior to Merck, Dr. Milligan served in advancing leadership roles in Research and Development at both Genentech and Amgen. In her role, Dr. Milligan oversees the organization's scientific, medical and regulatory capabilities in support of its diverse portfolio and long-term vision. She served as the Senior Vice President and Head of Global Regulatory Affairs and Clinical Safety from 2015 to 2020, where her responsibilities included leadership of the global clinical and CMC regulatory functions, as well as global clinical safety and pharmacovigilance for Merck Research Laboratories since 2015 until 2020. She served on the Board of Directors of the Drug Information Association (DIA) from 2011 to 2017, including serving as Chair between 2015 and 2016. Prior to joining Merck, from 2012 to 2015, Dr. Milligan was at Genentech, a member of the Roche Group, serving as Vice President, Product Development Regulatory and from 2002 to 2012, she was at Amgen Inc. in positions of increasing responsibility across legal and regulatory affairs functions. After serving as a General Medical Officer in the US Army Medical Corps, she began her corporate career as an attorney in healthcare and corporate law prior to joining the pharmaceutical industry. She formerly served as board chair of DIA, a global organization that mobilizes life sciences professionals across multiple disciplines involved in drug development to take a collaborative approach to solve common challenges. She served in the U.S. Army Medical Corps from 1987 to 1994. Dr. Milligan received a B.S. in Biology and a B.A. in Psychology from the University of California, Irvine. Dr. Milligan has served as co-sponsor of the Merck Women's Leadership Program. Dr. Milligan earned a Doctor of Medicine from the George Washington University School of Medicine as well as a Juris Doctor from Georgetown University Law Center.
Positions
- Company NameGossamer Bio, Inc.Stock CodeGOSSPositionIndependent DirectorColleagues
- FHFaheem HasnainCo-Founder, CEO, President & Chairman
- BGBryan GiraudoCOO & CFO
- RPRobert Paul SmithChief Commercial Officer
- CWChristian WaageExecutive Vice President, Technical Operations & General Counsel
- JAJeanine AnthonySenior Vice President of Marketing
- RJRussell J. CoxIndependent Director
- SMSandra MilliganIndependent Director
- SDSkye DrynanIndependent Director
- TOThomas O. DanielLead Independent Director
- Company NameSpyre Therapeutics, Inc.Stock CodeSYREPositionIndependent DirectorColleagues
- CTCameron TurtleCEO & Director
- JWJeffrey W. AlbersIndependent Chairman of the Board
- SLScott L. BurrowsChief Financial Officer
- HAHeidy Abreu King-JonesChief Legal Officer & Corporate Secretary
- SSSheldon SloanChief Medical Officer
- JGJanet Gunzner-TosteSenior Vice President of Operations
- LDLaurie D. StelzerIndependent Director
- KTKeith T. FlahertyMember of Scientific Advisory Board
